Related references
Note: Only part of the references are listed.Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans
Can Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
A second CD19 CAR T-cell infusion: yes or no?
Monica Casucci et al.
BLOOD (2021)
Predicting CAR-T cell Immunotherapy Success through ImmunoPET
Alessia Volpe et al.
CLINICAL CANCER RESEARCH (2021)
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
Ruimin Hong et al.
FRONTIERS IN IMMUNOLOGY (2021)
Determinants of response and resistance to CAR T cell therapy
Stefanie Lesch et al.
SEMINARS IN CANCER BIOLOGY (2020)
Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data
Prativa Sahoo et al.
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2020)
Data-driven analysis of a mechanistic model of CAR T cell signaling predicts effects of cell-to-cell heterogeneity
Colin G. Cess et al.
JOURNAL OF THEORETICAL BIOLOGY (2020)
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
Aman P. Singh et al.
MABS (2020)
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia
Matthew T. Witkowski et al.
CANCER CELL (2020)
Computational modelling of modern cancer immunotherapy
Damijan Valentinuzzi et al.
PHYSICS IN MEDICINE AND BIOLOGY (2020)
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Huiwen Jiang et al.
BIOMARKER RESEARCH (2020)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Andrew M. Brunner et al.
BLOOD (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A. Hay et al.
BLOOD (2019)
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy
Deni Hardiansyah et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu et al.
FRONTIERS IN IMMUNOLOGY (2019)
SIAN: software for structural identifiability analysis of ODE models
Hoon Hong et al.
BIOINFORMATICS (2019)
Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
Jiali Cheng et al.
FRONTIERS IN ONCOLOGY (2019)
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Najat Bouchkouj et al.
CLINICAL CANCER RESEARCH (2019)
Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia
Pablo Domizi et al.
BLOOD (2019)
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells
Andrew M. Stein et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai et al.
BLOOD ADVANCES (2019)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB
Shiqi Li et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Structural and practical identifiability analysis of outbreak models
Necibe Tuncer et al.
MATHEMATICAL BIOSCIENCES (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Jae H. Park et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
Differences in predictions of ODE models of tumor growth: a cautionary example
Hope Murphy et al.
BMC CANCER (2016)
Employing dynamical computational models for personalizing cancer immunotherapy
Zvia Agur et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Marco Ruella et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
How I treat relapsed childhood acute lymphoblastic leukemia
Franco Locatelli et al.
BLOOD (2012)
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Clinical Trial Simulation: A Review
N. Holford et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Novel metaheuristic for parameter estimation in nonlinear dynamic biological systems
Maria Rodriguez-Fernandez et al.
BMC BIOINFORMATICS (2006)
Share Paper
